Cremations, burials of unclaimed bodies to start this week, says NLHS
Dozens of bodies being kept in long-term storage by Newfoundland and Labrador Health Services will soon be buried, says a health authority chief operating officer.
CBC News first reported 28 bodies were being stored in freezer units outside of the Health Sciences Centre in St. John's due to a lack of space in the morgue in March, 2024. The morgue doubles as the Office of the Chief Medical Examiner.
The freezers were later relocated to a hospital parking garage where a new, expanded morgue was constructed.
On Monday, eastern-urban zone COO Ron Johnson announced Barrett's Funeral Home had been awarded the contract to carry out the burials.
"This week we had a lot of information come through after the posting went online. So this week some cremations and burials will start and we're working our way through the process," Johnson told reporters.
There are approximately 26 bodies currently in storage, Johnson said, but added the number is known to fluctuate.
"I think it's a little less today, but it'll be a lot less … when the week is over," he said.
CBC News asked Barrett's for an interview on Tuesday, but president Shane Mouland said he wasn't available.
"Please be assured that these cremations and burials will be carried out with the utmost care, dignity, and professionalism. Our team is working closely with NLHS to ensure each individual is respectfully laid to rest in a timely manner," he said in an email.
According to the amended legislation, which was filed on Dec. 24 and came into effect on Jan. 1, the health authority has the power to bury unclaimed bodies after two weeks of searching for next of kin and then five days after the person is posted on a dedicated website.
In May, CBC News reported Newfoundland and Labrador Health Services hadn't buried a single body since legislation came into effect and the website wasn't public.
At the time, health authority spokesperson Mikaela Etchegary said the delay was due to the need to finalize "operationalizing the legislation."
On May 28, a total of 26 names were posted on the website with a deadline of June 4 for people to respond in order to claim the body.
In response, several community efforts were launched to bury some of those individuals in their hometowns.
Other regions dealing with increasing numbers of bodies going unclaimed have brought in public memorial ceremonies to mark their burials.
In a statement to CBC News, health authority spokesperson Jon Oake said something of that nature isn't in the works at the moment.
"While group ceremonies are not planned, we continue to explore meaningful ways to collectively honour unclaimed individuals. Community partnerships and consultation play a key role in shaping this important work," he wrote.
In a statement dated June 3, seniors' advocate Susan Walsh said she had spoken with staff regarding how the deceased will be handled and was assured the wishes of the deceased, if known, would be carried out.
She was also told NLHS will make sure the deceased are sent back to their home communities for burial, and permanent markers with the person's name will be erected at the grave site.
"With the new process and timelines outlined in legislation, this unfortunate situation should be resolved going forward," wrote Walsh.
Download our free CBC News app to sign up for push alerts for CBC Newfoundland and Labrador. Sign up for our daily headlines newsletter here. Click here to visit our landing page.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Stewardship Cuts IV Treatment for Paediatric Bone Infections
TOPLINE: A hospital-based antimicrobial stewardship program (ASP) using post-prescription review and feedback (PPRF) significantly decreased intravenous (IV) antibiotic duration, length of hospital stay, and reliance on third-generation cephalosporin in paediatric bone and joint infections over 5 years. METHODOLOGY: This single-centre, quasi-experimental study evaluated the effect of a PPRF-based multifaceted ASP on antibiotic use, treatment duration, and length of hospital stay in paediatric acute haematogenous bone and joint infections (AH-BJIs). This study included 285 children: 60 in the pre-ASP (2015-2016; mean age, 1.9 years; 50% boys) and 225 in the post-ASP (2017-2023; mean age, 2.9 years; 67.5% boys). Data on demographics, clinical features, microbiology, and treatment were collected from electronic medical records. Primary outcomes were parenteral/oral antibiotic duration, length of hospital stay, and clinical outcomes (sequelae, readmission, and mortality). TAKEAWAY: The median IV antibiotic duration and length of hospital stay in children with AH-BJIs were both significantly reduced after ASP implementation, dropping from 8.5 (interquartile range [IQR], 7.0-12.0) to 7 (IQR, 4.5-8.0) days and from 8.5 (IQR, 7.0-11.0) to 7 (IQR, 5.0-9.0) days, respectively (P < .001 for both). Post-2020, broad-spectrum antibiotic use significantly declined, with third-generation cephalosporin use fell from 81% to 10% in children aged 5 years or younger and cloxacillin use declined by 60.0% in children older than 5 years in favour of narrower spectrum cefazolin (P < .001 for both). Methicillin-susceptible Staphylococcus aureus was the most common pathogen (22.8%), followed by Kingella kingae (10.9%), which was found in only children younger than 4 years. Blood cultures were positive in 29.3% of cases. Among 52 children with soft-tissue/subperiosteal abscesses (46 occurring post-ASP), the median oral antibiotic duration was 41 days, with total treatment lasting 47 days; the ASP maintained safety, with no increase seen in sequelae (6.3% overall), readmissions (3.3% in the pre-ASP vs 3.6% in the post-ASP), and mortality (0%). IN PRACTICE: "After ASP implementation, the length of parenteral antibiotic treatment, length of hospital stay, and 3rd generation cephalosporin use in children with AH-BJI were reduced safely," the authors wrote. SOURCE: This study was led by Aina Font, Pharmacy Department, Consorci Hospitalari de Vic, Vic, Spain. It was published online on June 18, 2025, in the European Journal of Pediatrics. LIMITATIONS: This single-centre study had several limitations, such as the unbalanced sample size and inclusion of neonates, which may have affected generalisability; the findings based on local epidemiology may not apply to other settings. This study did not evaluate treatment days per 1000 admissions, cost-effectiveness, COVID-19 impact, diagnostic advances, and staff turnover effects, nor it systematically monitor prescriber adherence or satisfaction with the stewardship program. DISCLOSURES: No funding was secured for this study. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Forbes
an hour ago
- Forbes
Is AI About To Solve A $55 Billion Healthcare Problem?
Mika Newton is CEO of xCures, using state-of-the-art AI to process all types of medical records, turning data chaos into clinical clarity. Each year, the U.S. loses more than $55 billion due to missed prevention. This includes colonoscopies that were never scheduled, A1c tests that were forgotten and statins that stayed on the pharmacy shelf. In a value-based care environment, these oversights cause avoidable crises, drain shared-savings pools and inflate emergency care costs. Yet today, most health systems still rely on spreadsheets, printed lab reports and manual chart reviews to identify and address lapses. The result is unfortunate and predictable: Care slips through the cracks, and no one notices until it's too late. This so-called 'gap' in care consists of evidence-based actions that haven't occurred. Guideline-setting organizations such as USPSTF, ADA, NCCN and CMS outline thousands of these actions, ranging from mammogram scheduling to the follow-up times after a heart failure discharge. Electronic health records can (and do) help catch some of these lapses before they cause significant damage or affect patients. Still, many are buried in unstructured notes, siloed imaging systems or social risk factors that traditional rules engines can't easily parse. We need fast, precise and proactive tools to improve health outcomes and reduce costs. This is where artificial intelligence is on the cusp of addressing missed prevention. AI systems can read millions of clinical notes. This is a feat unthinkable just a few years ago. In fact, one health AI company, Astrata, reported that its NLP platform accelerated gap-closure efficiency by six to 38 times, depending on the measure. This is a topic I've been passionate about for years. I've worked on applying simulation models of human physiology and health systems to predict clinical outcomes and optimize care delivery. I've helped build AI tools that automate literature review and evidence synthesis, which has taught me valuable knowledge buried in unstructured data. Furthermore, I've observed how often essential details get missed, not because people don't care, but because the systems weren't built to help them catch everything. Because these models continuously learn and evolve, they integrate new guideline releases within days, rather than waiting for the next annual update. Most importantly, AI makes these insights actionable by assigning risk scores to patients, which helps care teams prioritize outreach based on potential benefit. That means resources go where they matter most. We're already seeing this shift take place in the real world. In 2024, AmeriHealth Caritas and Prospect Medical won a KLAS Points of Light award for demonstrating that AI could close HEDIS care gaps more efficiently than manual review. In March 2025, Navina, a company developing an AI copilot for physicians, raised $55 million to scale its work, which is strong evidence that the return on investment for AI in care coordination is already apparent to the market. Meanwhile, the cost of doing nothing continues to climb. Preventable care gaps are estimated to account for 30 cents of every healthcare dollar in the United States. The financial upside of closing these gaps is significant. Fewer unmanaged diabetics means fewer ER visits, which improves shared savings and capitation margins. In Medicare Advantage, every half-star jump in plan ratings can increase revenue by more than 2%. When AI tools help document chronic conditions previously hidden in free-text notes, the accuracy of risk adjustment scores improves, along with the per-member payments tied to them. Across multiple payer case studies, AI gap-closure programs deliver first-year returns of three to one, even before factoring in long-term clinical gains. These systems typically work by ingesting a wide variety of data, including electronic health record (EHR) and claims feeds, pharmacy records, lab results, device data and social-risk indices. AI models then map each patient's status against current guidelines using codified rules or clinical knowledge graphs. Predictive risk models help prioritize which patients should be contacted first, and those alerts are integrated directly into clinicians' existing workflows, avoiding the friction of switching systems or portals. In parallel, real-time dashboards link each closed gap to downstream outcomes, providing visibility into the impact of each intervention. With the ONC's HTI-1 Final Rule expected to take effect this year, AI vendors must disclose the training data attributes and bias mitigation techniques used in their models. This regulatory change adds a layer of transparency that will likely empower buyers to make more informed choices. To see how this all works, consider Maria, a 58-year-old hypothetical diabetic patient who hasn't filled her statin prescription. The AI platform notices her unfilled script, her most recent LDL results and two missed primary care appointments. It recognizes that she lives in a transportation desert. Within seconds, the system sends her a message offering a lower-cost statin alternative and a ride-share voucher. When the pharmacy claim posts, the care gap closes automatically. Multiply that moment across thousands of patients, and it becomes clear how AI can save money while improving population health. To do this right, we need to be clear about the problem. Changing a process is hard, so the best tools earn trust because they help immediately. That's what makes the difference. In healthcare, patient outcomes are paramount. However, tools must also show return on investment (ROI) through increased revenue and ensure user adoption through better workflow. Any tool you vet or develop should make these capabilities immediately apparent. Additionally, make sure you understand bias. It is always there. This phenomenon is natural, but you must understand and quantify the bias. For example, most Polygenic Risk Score (PRS) models for breast cancer, which are used to predict genetic susceptibility, were initially developed using data from individuals of European descent. As a result, these models underperformed in Black, Hispanic and Asian populations. Researchers created ancestry-specific PRS models by training on genomic data from non-European cohorts. This kind of proactive work to address bias is essential in any AI solution you build or buy. The truth is that bending the cost curve isn't possible unless you know where it's broken. Artificial intelligence now allows us to see those cracks as they form and points to who can fix them. The incentives are aligned. The technology is mature. The upside is enormous. The next move is yours. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Yahoo
an hour ago
- Yahoo
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, the Company's proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD). The first patient was enrolled at Yale School of Medicine's Department of Psychiatry, marking a significant milestone in the trial. The trial is evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to explore its potential in reducing alcohol cravings and consumption. This first-in-human study represents a pivotal step toward developing a groundbreaking treatment for individuals struggling with AUD. Eligible subjects for the clinical trial, among others, are individuals aged 18 to 60. Participants may be either non-treatment-seeking individuals who report heavy binge drinking (defined as at least five standard drinks in a day for men or at least four for women) on at least five days in the past month prior to screening, or treatment-seeking individuals diagnosed with Alcohol Use Disorder (AUD) per DSM-5 criteria, who report at least four binge drinking days in the month prior to screening. All subjects must express a desire to reduce or stop drinking. For more information: Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine said:'This advancement brings us one step closer to offering an innovative solution for those affected by AUD, a condition with significant unmet medical needs. The substance use disorder treatment market in the U.S. alone was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029. Moreover, there are hundreds of millions of individuals around the globe afflicted by AUD. However, the market has been constrained due to the limited effectiveness and adverse side effects of current treatment options. We are executing on our development strategy and are optimistic about the potential of our MEAI-based therapy to offer a safe, effective solution that can transform lives.' The Phase I/IIa clinical trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, while the Company is valuating additional clinical sites. Clearmind remains committed to advancing its robust intellectual property portfolio and pioneering psychedelic-derived therapeutics to address global health challenges. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND' and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relationsinvest@ Telephone: (604) 260-1566US: CMND@ General InquiriesInfo@ Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses conducting its Phase I/IIa clinical trial, developing a treatment for individuals struggling with AUD, the size of the substance use disorder treatment market, executing its development strategy, valuating additional clinical sites, and that it remains committed to advancing its robust intellectual property portfolio and pioneering psychedelic-derived therapeutics to address global health challenges. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
